MASTERMIND: Bringing Microbial Diagnostics to the Clinic

Antibacterial Resistance Leadership Group (ARLG)

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

New diagnostics are urgently needed to address emerging antimicrobial resistance. The Antibacterial Resistance Leadership Group proposes a strategy called MASTERMIND (Master Protocol for Evaluating Multiple Infection Diagnostics) for advancement of infectious diseases diagnostics. The goal of this strategy is to generate the data necessary to support US Food and Drug Administration clearance of new diagnostic tests by promoting research that might not have otherwise been feasible with conventional trial designs. MASTERMIND uses a single subject's sample(s) to evaluate multiple diagnostic tests at the same time, providing efficiencies of specimen collection and characterization. MASTERMIND also offers central trial organization, standardization of methods and definitions, and common comparators.

Original languageEnglish (US)
Pages (from-to)355-360
Number of pages6
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume64
Issue number3
DOIs
StatePublished - Feb 1 2017

Fingerprint

Routine Diagnostic Tests
Infection
Specimen Handling
United States Food and Drug Administration
Communicable Diseases
Organizations
Research

Keywords

  • communicable diseases
  • molecular diagnostic techniques
  • reference standards.

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

MASTERMIND : Bringing Microbial Diagnostics to the Clinic. / Antibacterial Resistance Leadership Group (ARLG).

In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 64, No. 3, 01.02.2017, p. 355-360.

Research output: Contribution to journalArticle

@article{3d57902ef11b47eaa018f9612fe44477,
title = "MASTERMIND: Bringing Microbial Diagnostics to the Clinic",
abstract = "New diagnostics are urgently needed to address emerging antimicrobial resistance. The Antibacterial Resistance Leadership Group proposes a strategy called MASTERMIND (Master Protocol for Evaluating Multiple Infection Diagnostics) for advancement of infectious diseases diagnostics. The goal of this strategy is to generate the data necessary to support US Food and Drug Administration clearance of new diagnostic tests by promoting research that might not have otherwise been feasible with conventional trial designs. MASTERMIND uses a single subject's sample(s) to evaluate multiple diagnostic tests at the same time, providing efficiencies of specimen collection and characterization. MASTERMIND also offers central trial organization, standardization of methods and definitions, and common comparators.",
keywords = "communicable diseases, molecular diagnostic techniques, reference standards.",
author = "{Antibacterial Resistance Leadership Group (ARLG)} and Robin Patel and Tsalik, {Ephraim L.} and Elizabeth Petzold and Fowler, {Vance G.} and Klausner, {Jeffrey D.} and Scott Evans",
year = "2017",
month = "2",
day = "1",
doi = "10.1093/cid/ciw788",
language = "English (US)",
volume = "64",
pages = "355--360",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - MASTERMIND

T2 - Bringing Microbial Diagnostics to the Clinic

AU - Antibacterial Resistance Leadership Group (ARLG)

AU - Patel, Robin

AU - Tsalik, Ephraim L.

AU - Petzold, Elizabeth

AU - Fowler, Vance G.

AU - Klausner, Jeffrey D.

AU - Evans, Scott

PY - 2017/2/1

Y1 - 2017/2/1

N2 - New diagnostics are urgently needed to address emerging antimicrobial resistance. The Antibacterial Resistance Leadership Group proposes a strategy called MASTERMIND (Master Protocol for Evaluating Multiple Infection Diagnostics) for advancement of infectious diseases diagnostics. The goal of this strategy is to generate the data necessary to support US Food and Drug Administration clearance of new diagnostic tests by promoting research that might not have otherwise been feasible with conventional trial designs. MASTERMIND uses a single subject's sample(s) to evaluate multiple diagnostic tests at the same time, providing efficiencies of specimen collection and characterization. MASTERMIND also offers central trial organization, standardization of methods and definitions, and common comparators.

AB - New diagnostics are urgently needed to address emerging antimicrobial resistance. The Antibacterial Resistance Leadership Group proposes a strategy called MASTERMIND (Master Protocol for Evaluating Multiple Infection Diagnostics) for advancement of infectious diseases diagnostics. The goal of this strategy is to generate the data necessary to support US Food and Drug Administration clearance of new diagnostic tests by promoting research that might not have otherwise been feasible with conventional trial designs. MASTERMIND uses a single subject's sample(s) to evaluate multiple diagnostic tests at the same time, providing efficiencies of specimen collection and characterization. MASTERMIND also offers central trial organization, standardization of methods and definitions, and common comparators.

KW - communicable diseases

KW - molecular diagnostic techniques

KW - reference standards.

UR - http://www.scopus.com/inward/record.url?scp=85027452901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027452901&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw788

DO - 10.1093/cid/ciw788

M3 - Article

C2 - 27927867

AN - SCOPUS:85027452901

VL - 64

SP - 355

EP - 360

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -